A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model
A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model
复制标题
DOI：
10.1007/s10384-008-0530-1
复制
发表时间：
2008-05-01
影响因子：
2.4
通讯作者：
Gordon, Y. J.
中科院分区：
文献类型：
--
作者：
Kowalski, Regis P.;Romanowski, Eric G.;Gordon, Y. J.
目的：比较第四代氟喹诺酮类药物莫西沙星和第三代氟喹诺酮类药物左氧氟沙星对氟喹诺酮耐药、耐甲氧西林金黄色葡萄球菌(FQrMRSA)眼内炎的预防作用。每种方案15只兔左眼每隔15分钟滴入一次，持续1小时。麻醉后房水内注入FQrMRSA 2×10(4)CFU。立即滴1滴，24小时后滴4滴，24小时后进行眼内炎的临床分级。结果：外用莫西沙星(12/15，80%)对临床眼内炎的预防作用明显优于左氧氟沙星(2/15，13%)或生理盐水(2/15，13%)(P=0.0001)。莫西沙星治疗组的临床总积分中位数(1.0)显著低于左氧氟沙星组(2 0.0)和生理盐水组(2 3.0)(P=0.0004)。左氧氟沙星(8/15，53%)和生理盐水(1/15，7%)治疗的培养阴性眼的发生率低于莫西沙星(12/15，80%)。结论：这项体内研究表明，第四代FQ莫西沙星可能比第三代FQ左氧氟沙星更有效地预防实验性FQrMRSA。眼内炎。
Purpose: Moxifloxacin, a fourth-generation fluoroquinolone (FQ), was compared to levofloxacin, a thirdgeneration FQ, for preventing FQ-resistant, methicillin-resistant Staphylococcus aureus (FQrMRSA) endophthalmitis in a rabbit model.Methods: Three regimens of topical treatments (moxifloxacin 0.5%, levofloxacin 0.5%, and saline) were tested to prevent endophthalmitis. For each regimen, drops were instilled every 15 min for 1 h into the left eyes of 15 rabbits. After anesthesia, 2 x 10(4) cfu of FQrMRSA was injected into the aqueous. One drop of treatment was given immediately, and another four drops were applied over 24 h. At 24 h, the eyes were clinically graded for endophthalmitis. After the rabbits were sacrificed, the aqueous and vitreous were tapped for bacterial colony counts.Results: Topical moxifloxacin (12/15, 80%) significantly (P = 0.0001) prevented clinical endophthalmitis in more rabbits than levofloxacin (2/15, 13%) or saline (2/15, 13%). The total median clinical score for moxifloxacin treatment (1.0) was significantly (P = 0.0004) lower than that for levofloxacin (20.0) or saline (23.0). Culture-negative eyes were less frequent for levofloxacin (8/15, 53%) and saline (1/15, 7%) treatments than for moxifloxacin treatment (12/15, 80%).Conclusion: This in vivo study indicates that moxifloxacin, a fourth-generation FQ, may be more effective than levofloxacin, a third-generation FQ, in preventing experimental FQrMRSA. endophthalmitis.